Ignite Creation Date:
2024-05-06 @ 3:34 PM
Last Modification Date:
2024-10-26 @ 1:52 PM
Study NCT ID:
NCT04676243
Status:
WITHDRAWN
Last Update Posted:
2022-05-25
First Post:
2020-12-09
Brief Title:
Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physicians Choice in Newly Diagnosed FLT3-ITD AML
Sponsor:
University Hospital Heidelberg
Organization:
University Hospital Heidelberg
Organization Data
Organization:
University Hospital Heidelberg
Class:
OTHER
Study ID:
HeLeNe 20-04
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
University Hospital Heidelberg
Lead Sponsor Class:
OTHER
Responsible Party:
Prof Dr Richard F Schlenk
Responsible Party Title:
Assistant medical director
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
University Hospital Heidelberg
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Daiichi Sankyo Europe GmbH a Daiichi Sankyo Company | INDUSTRY |